Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for NexImmune, Inc. (NEXI : NSDQ)
 
 • Company Description   
NexImmune Inc. is a clinical-stage biotechnology company. It engages in developing a novel approach to immunotherapy designed to employ the body's own T cells to generate a specific, potent and durable immune response that mimics natural biology. NexImmune Inc. is based in GAITHERSBURG, Md.

Number of Employees: 74

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.02 Daily Weekly Monthly
20 Day Moving Average: 142,763 shares
Shares Outstanding: 22.84 (millions)
Market Capitalization: $46.14 (millions)
Beta: 2.00
52 Week High: $19.50
52 Week Low: $1.72
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -24.91% -17.78%
12 Week -21.09% -11.32%
Year To Date -56.18% -46.47%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
9119 GAITHER ROAD
-
GAITHERSBURG,MD 20877
USA
ph: 301-825-9810
fax: -
crubin@neximmune.com http://www.neximmune.com
 
 • General Corporate Information   
Officers
Kristi Jones - President;ChiefExecutive Officer and Director
Sol J. Barer - Chairman of the Board of Directors
John Trainer - Chief Financial Officer
Alan S. Roemer - Director
Tim Bertram - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 65344D109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 22.84
Most Recent Split Date: (:1)
Beta: 2.00
Market Capitalization: $46.14 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.66 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.16 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.66
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 7.04%
vs. Previous Quarter: 2.94%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -63.41
12/31/21 - -49.39
09/30/21 - -67.24
ROA
03/31/22 - -58.83
12/31/21 - -46.42
09/30/21 - -48.50
Current Ratio
03/31/22 - 10.14
12/31/21 - 11.96
09/30/21 - 13.28
Quick Ratio
03/31/22 - 10.14
12/31/21 - 11.96
09/30/21 - 13.28
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 3.08
12/31/21 - 3.67
09/30/21 - 4.28
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©